Multidrug-resistant tuberculosis

This trial is testing two tuberculosis (TB) vaccines—VPM1002 and a repeat BCG vaccination—in pre-adolescents aged 8-14 who were vaccinated at birth. The goal is to see if these vaccines are safe and trigger a strong immune response in children both with and without HIV, and in th…

This study tests a new combination of five oral drugs (bedaquiline, delamanid, levofloxacin, linezolid, and clofazimine) for treating multidrug-resistant tuberculosis (MDR-TB). The goal is to see if a shorter treatment course (16 to 40 weeks) can effectively cure the infection wi…

This study looks at whether having a nurse case manager helps people with multidrug-resistant tuberculosis (MDR-TB) and HIV complete their long treatment. About 3,600 patients in South Africa are involved. Half of the clinics have a nurse case manager to guide care, while the oth…

This phase 3 trial is testing a 6-month, all-oral combination of four drugs (bedaquiline, delamanid, linezolid, and levofloxacin or clofazimine) to treat rifampin-resistant tuberculosis in Chinese teenagers and adults aged 12 and older. The goal is to see if this shorter regimen …

This study evaluates a new PCR test (Bioneer Q-RFIA kit) for quickly and accurately detecting tuberculosis (TB) and resistance to key antibiotics. About 2,350 adults with TB symptoms will provide samples to see how well the test works compared to standard methods. The goal is to …